cagrisema novo nordisk - Search News

Novo Nordisk's next-gen obesity drug Cagrisema

Hosted on MSN · 19h

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

The New York Times · 14h

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

YAHOO!Finance · 1d

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk Stock Rises

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.

Investopedia on MSN · 22h

Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition.

Seeking Alpha · 19h

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO stock from hold to buy.

14hon MSN

Novo doubles down on next-gen weight loss therapy despite early setback

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

11h

Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

1d

Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results